A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
← catalyst calendarNCT05851443 · readout in 93 d
Sponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
247actual
Sites
82
Countries
Argentina, Canada, Germany +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-11 | actual | When the study began enrolling |
| Primary completion | 2026-11-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-05 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Asthma
Interventions
- Drug: povorcitinib — also filed as INCB54707
- Other: placebo
- Drug: ICS-LABA
Primary outcome
what the primary-completion date above is the date OFAbsolute change in pre-bronchodilator forced expiratory volume in the first 1 second (pre-BD FEV1)
measured Baseline ; Week 24
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed